Journal articles on the topic 'Trastuzumab therapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Trastuzumab therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Park, Juin, Woo Sun Kwon, Sun Kyoung Kang, Tae Soo Kim, Jihyun Hwang, Sang Woo Cho, Kyunggon Kim, Hyun Cheol Chung, and Sun Young Rha. "Abstract 5079: Comparative proteome analysis for predicting the prognosis of trastuzumab-based therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5079. http://dx.doi.org/10.1158/1538-7445.am2022-5079.
Full textOca??a, Alberto, Juan J. Cruz, and Atanasio Pandiella. "Trastuzumab and Antiestrogen Therapy." American Journal of Clinical Oncology 29, no. 1 (February 2006): 90–95. http://dx.doi.org/10.1097/01.coc.0000190274.00570.0a.
Full textEbb, David, Paul Meyers, Holcombe Grier, Mark Bernstein, Richard Gorlick, Steven E. Lipshultz, Mark Krailo, et al. "Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group." Journal of Clinical Oncology 30, no. 20 (July 10, 2012): 2545–51. http://dx.doi.org/10.1200/jco.2011.37.4546.
Full textDormann, Clemens. "Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives." Breast Care 15, no. 6 (2020): 570–78. http://dx.doi.org/10.1159/000512328.
Full textLee, S. W., H. F. Kamaruzaman, and J. Sabirin. "Trastuzumab as An Adjuvant Therapy for Early Breast Cancer." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 70s. http://dx.doi.org/10.1200/jgo.18.31500.
Full textGabric, Ivo Darko, Ljubica Vazdar, Hrvoje Pintaric, Danijel Planinc, Robert Separovic, Mario Stefanovic, Matias Trbusic, Marijana Jazvic, Ozren Vinter, and Zeljko Soldic. "Cardiotoxicity caused by trastuzumab therapy." Cardiologia Croatica 9, no. 9-10 (October 29, 2014): 433. http://dx.doi.org/10.15836/ccar.2014.433.
Full textBrann, Alison M., Melody A. Cobleigh, and Tochi M. Okwuosa. "Cardiovascular Monitoring With Trastuzumab Therapy." JAMA Oncology 2, no. 9 (September 1, 2016): 1123. http://dx.doi.org/10.1001/jamaoncol.2016.1288.
Full textKeene, K. S., L. C. Klepczyk, R. Meredith, A. Forero-Torres, J. T. Carpenter, H. Krontiras, M. Hyatt, Y. Li, and J. F. De Los Santos. "An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events." Journal of Clinical Oncology 29, no. 27_suppl (September 20, 2011): 121. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.121.
Full textOgawa, Lauren, and Deborah Lindquist. "Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease." Case Reports in Oncology 11, no. 3 (December 19, 2018): 855–60. http://dx.doi.org/10.1159/000494264.
Full textHassan, Chadi, Florence Correal, Gabriel Vézina, Louise Yelle, and Jean-Philippe Adam. "Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report." Journal of Oncology Pharmacy Practice 26, no. 7 (March 19, 2020): 1780–84. http://dx.doi.org/10.1177/1078155220910252.
Full textMates, M., G. G. Fletcher, O. C. Freedman, A. Eisen, S. Gandhi, M. Trudeau, and S. F. Dent. "Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline." Current Oncology 22 (December 18, 2014): 114. http://dx.doi.org/10.3747/co.22.2322.
Full textDi Lauro, Vincenzo, Elena Torrisi, Ettore Bidoli, Daniela Quitadamo, Sara Cecco, and Andrea Veronesi. "Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series." Journal of Oncology 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/198412.
Full textFreedman, Rachel A., Ines Maria Vaz Duarte Luis, Nancy Lin, Joyce Lii, Eric P. Winer, and Nancy Lynn Keating. "Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 616. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.616.
Full textReeder-Hayes, Katherine, Sharon Peacock Hinton, Ke Meng, Lisa A. Carey, and Stacie B. Dusetzina. "Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer." Journal of Clinical Oncology 34, no. 17 (June 10, 2016): 2003–9. http://dx.doi.org/10.1200/jco.2015.65.8716.
Full textKrstić, Ivana, Marina Deljanin Ilić, Svetislav Vrbić, and Ivica Pejčić. "Significance of Echocardiography in the Assessment of Left Ventricular Function in Patients Receiving Combined Adjuvant Treatment with Anthracyclines and Trastuzumab / Značaj ehokardiografije u proceni funkcije leve komore kod bolesnica na adjuvantnoj terapji (kombinovana terapija antraciklinima i trastuzumabom)." Acta Facultatis Medicae Naissensis 32, no. 3 (September 1, 2015): 181–87. http://dx.doi.org/10.1515/afmnai-2015-0018.
Full textTripathy, Debu, Dennis J. Slamon, Melody Cobleigh, Andrew Arnold, Mansoor Saleh, Joanne E. Mortimer, Maureen Murphy, and Stanford J. Stewart. "Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression." Journal of Clinical Oncology 22, no. 6 (March 15, 2004): 1063–70. http://dx.doi.org/10.1200/jco.2004.06.557.
Full textCortés, Javier, Pierre Fumoleau, Giulia Valeria Bianchi, Teresa M. Petrella, Karen Gelmon, Xavier Pivot, Shailendra Verma, et al. "Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer." Journal of Clinical Oncology 30, no. 14 (May 10, 2012): 1594–600. http://dx.doi.org/10.1200/jco.2011.37.4207.
Full textWaller, Cornelius F., Aleksei Manikhas, Eduardo J. Pennella, Igor Bondarenko, Guzel Mukhametshina, Maria Luisa Abesanis Tiambeng, Charuwan Akewanlop, et al. "Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1021. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1021.
Full textYu, Liuwen, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, and Chuan Wang. "Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of Oncology 2020 (March 16, 2020): 1–13. http://dx.doi.org/10.1155/2020/5169278.
Full textMaddox, Adam L., Matthew S. Brehove, Kiarash R. Eliato, Andras Saftics, Eugenia Romano, Michael F. Press, Joanne Mortimer, et al. "Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer." Cancers 14, no. 11 (June 4, 2022): 2795. http://dx.doi.org/10.3390/cancers14112795.
Full textIqbal, Muhammad Shahid, Ghazia Shaikh, Sanjoy Chatterjee, Helen Cocks, and Josef Kovarik. "Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma." Case Reports in Oncological Medicine 2014 (2014): 1–4. http://dx.doi.org/10.1155/2014/162534.
Full textGutting, Tobias, Nadine Schulte, Sebastian Belle, Johannes Betge, Nicolai Härtel, Jürgen Wilke, Jürgen Weers, Matthias P. Ebert, and Tianzuo Zhan. "Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment." Journal of Gastrointestinal and Liver Diseases 28, no. 4 (December 9, 2019): 503–7. http://dx.doi.org/10.15403/jgld-397.
Full textJoy, A. A., and J. R. Mackey. "The role of platinum-based therapy for HER-2-positive breast cancer." Breast Cancer Online 9, no. 4 (February 17, 2006): 1–7. http://dx.doi.org/10.1017/s1470903105004712.
Full textSuvarna, S. K. "Cardiac pathology of fatal trastuzumab therapy." Journal of Clinical Pathology 61, no. 1 (September 14, 2007): 143–44. http://dx.doi.org/10.1136/jcp.2007.047464.
Full textHortobagyi, Gabriel N. "Optimal duration of therapy with trastuzumab." Seminars in Oncology 28, no. 5N (October 2001): 33–40. http://dx.doi.org/10.1053/sonc.2001.28548.
Full textHORTOBAGYI, G. "Optimal duration of therapy with trastuzumab." Seminars in Oncology 28 (October 2001): 33–40. http://dx.doi.org/10.1016/s0093-7754(01)90280-5.
Full textHua, Xin, Xi-Wen Bi, Jian-Li Zhao, Yan-Xia Shi, Ying Lin, Zhi-Yong Wu, Yuan-Qi Zhang, et al. "Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)." Clinical Cancer Research 28, no. 4 (November 22, 2021): 637–45. http://dx.doi.org/10.1158/1078-0432.ccr-21-3435.
Full textYuan, Zhongyu, Jia-Jia Huang, Xin Hua, Jian-Li Zhao, Ying Lin, Yuan-Qi Zhang, Zhiyong Wu, et al. "Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 1003. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1003.
Full textChurch, David N., and Chris G. A. Price. "A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S35. http://dx.doi.org/10.4137/cmt.s35.
Full textJackson, Christopher, Leila Finikarides, and Alexandra L. J. Freeman. "The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis." PLOS ONE 17, no. 12 (December 1, 2022): e0275321. http://dx.doi.org/10.1371/journal.pone.0275321.
Full textHojan, Katarzyna, Karolina Gerreth, Danuta Procyk, Krystian Mania, Anna Zalewska, and Mateusz Maciejczyk. "Redox Status Response of Physical Exercise Training in Women with Breast Cancer during Trastuzumab Therapy." Healthcare 10, no. 10 (October 15, 2022): 2039. http://dx.doi.org/10.3390/healthcare10102039.
Full textHua, Jun, Zhe Zhang, Lili Zhang, Yan Sun, and Yuan Yuan. "UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells." Cancer Chemotherapy and Pharmacology 88, no. 4 (June 19, 2021): 633–42. http://dx.doi.org/10.1007/s00280-021-04303-4.
Full textWang, Wei, Zhenhua Hu, Yu Huang, Huilin Zheng, Qiang Sun, Qifan Yang, Yuan Zhang, Linshi Zhang, and Weilin Wang. "Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo." BioMed Research International 2019 (March 25, 2019): 1–12. http://dx.doi.org/10.1155/2019/9205851.
Full textMitri, Zahi, Tina Constantine, and Ruth O'Regan. "The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy." Chemotherapy Research and Practice 2012 (December 20, 2012): 1–7. http://dx.doi.org/10.1155/2012/743193.
Full textSpector, Neil L., and Kimberly L. Blackwell. "Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer." Journal of Clinical Oncology 27, no. 34 (December 1, 2009): 5838–47. http://dx.doi.org/10.1200/jco.2009.22.1507.
Full textBlondeaux, Eva, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Claudia Bighin, Federico Sottotetti, Filippo Montemurro, et al. "Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study." ESMO Open 5, no. 4 (August 2020): e000719. http://dx.doi.org/10.1136/esmoopen-2020-000719.
Full textChung, Clement, and Masha S. H. Lam. "Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer." American Journal of Health-System Pharmacy 70, no. 18 (September 15, 2013): 1579–87. http://dx.doi.org/10.2146/ajhp120735.
Full textBloom, Meghan J., Patrick N. Song, John Virostko, Thomas E. Yankeelov, and Anna G. Sorace. "Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer." Cancers 14, no. 17 (August 31, 2022): 4234. http://dx.doi.org/10.3390/cancers14174234.
Full textLanning, Ryan Michael, Nadeem Riaz, Monica Morrow, Tracy-Ann Moo, Mahmoud El-Tamer, Kate Krause, Yu Chen, Xin Pei, Simon N. Powell, and Alice Y. Ho. "Effect of adjuvant trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-positive breast cancer treated with post-mastectomy radiation therapy." Journal of Clinical Oncology 31, no. 26_suppl (September 10, 2013): 61. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.61.
Full textFile, Danielle, Giuseppe Curigliano, and Lisa A. Carey. "Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer." American Society of Clinical Oncology Educational Book, no. 40 (May 2020): 3–13. http://dx.doi.org/10.1200/edbk_100023.
Full textUeno, Takayuki, Norikazu Masuda, Nobuaki Sato, Shoichiro Ohtani, Jun Yamamura, Nobuki Matsunami, Masahiro Kashiwaba, et al. "Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study." Japanese Journal of Clinical Oncology 50, no. 1 (December 10, 2019): 3–11. http://dx.doi.org/10.1093/jjco/hyz119.
Full textMohammed, Samer Imad, Aya Thaer Sabry, and Dania Thaer Sabry. "Assessment of Health Beliefs Among Iraqi Breast Cancer Patients in Baghdad using either Tamoxifen or Trastuzumab." Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512) 30, no. 2 (December 11, 2021): 113–21. http://dx.doi.org/10.31351/vol30iss2pp113-121.
Full textHester, Anna, Paul Gaß, Peter A. Fasching, Anne Katrin Krämer, Johannes Ettl, Joachim Diessner, Achim Wöckel, et al. "Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres." Geburtshilfe und Frauenheilkunde 80, no. 09 (September 2020): 924–31. http://dx.doi.org/10.1055/a-1226-6666.
Full textDorris, Kathleen, Melissa Widener, Vladimir Amani, Andrew Donson, Debra Schissel, Jessica Carson, Ashley Mettetal, et al. "EPCT-18. PHASE 0/I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii307. http://dx.doi.org/10.1093/neuonc/noaa222.140.
Full textSasse, Andre Deeke, Flavio Mavignier Carcano, Lucas Vieira dos Santos, and Joao Paulo Da S. N. Lima. "Efficacy of different anti-HER2 drugs in first-line therapy for advanced breast cancer: Systematic review and meta-analysis." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e11500-e11500. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11500.
Full textPal, S. K., A. Naeim, F. L. Wong, C. T. Chung, S. Bhatia, J. Mortimer, G. Somlo, S. Hurvitz, D. Villaluna, and A. Hurria. "Recommendation of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: A survey of oncologists." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 9547. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9547.
Full textOMAROVA, I. M., J. O. NURKETAEVA, and D. D. DOROGAN. "Calculation of the cost-effectiveness of subcutaneous administration of trastuzumab." Oncologia i radiologia Kazakhstana 55, no. 1 (March 31, 2020): 9–11. http://dx.doi.org/10.52532/2663-4864-2020-1-55-9-11.
Full textPrempree, T., and C. Wongpaksa. "Mutations of HER2 gene in HER2-positive metastatic breast cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 13118. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13118.
Full textMarinko, Tanja, Jure Dolenc, and Cvetka Bilban-Jakopin. "Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer." Radiology and Oncology 48, no. 2 (June 1, 2014): 105–12. http://dx.doi.org/10.2478/raon-2013-0040.
Full textAcevedo-Gadea, Carlos, Christos Hatzis, Gina Chung, Neal Fishbach, Kimberly Lezon-Geyda, Daniel Zelterman, Michael P. DiGiovanna, Lyndsay Harris, and Maysa M. Abu-Khalaf. "Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy." Breast Cancer Research and Treatment 150, no. 1 (February 2015): 157–67. http://dx.doi.org/10.1007/s10549-015-3292-8.
Full text